Abstract:Background Prenatal adverse environments can cause fetal intrauterine growth retardation (IUGR) and higher susceptibility to multiple diseases after birth, related to multi-organ development programming changes mediated by intrauterine overexposure to maternal glucocorticoids. As a glucocorticoid barrier, P-glycoprotein (P-gp) is highly expressed in placental syncytiotrophoblasts; however, the effect of P-gp on the occurrence of IUGR remains unclear. Methods Human placenta and fetal cord blood samples of IUGR fetuses were collected, and the related indexes were detected. Pregnant Wistar rats were administered with 30 mg/kg center dot d (low dose) and 120 mg/kg center dot d (high dose) caffeine from gestational day (GD) 9 to 20 to construct the rat IUGR model. Pregnant mice were administered with caffeine (120 mg/kg center dot d) separately or combined with sodium ferulate (50 mg/kg center dot d) from gestational day GD 9 to 18 to confirm the intervention target on fetal weight loss caused by prenatal caffeine exposure (PCE). The fetal serum/placental corticosterone level, placental P-gp expression, and related indicator changes were analyzed. In vitro, primary human trophoblasts and BeWo cells were used to confirm the effect of caffeine on P-gp and its mechanism. Results The placental P-gp expression was significantly reduced, but the umbilical cord blood cortisol level was increased in clinical samples of the IUGR neonates, which were positively and negatively correlated with the neonatal birth weight, respectively. Meanwhile, in the PCE-induced IUGR rat model, the placental P-gp expression of IUGR rats was decreased while the corticosterone levels of the placentas/fetal blood were increased, which were positively and negatively correlated with the decreased placental/fetal weights, respectively. Combined with the PCE-induced IUGR rat model, in vitro caffeine-treated placental trophoblasts, we confirmed that caffeine decreased the histone acetylation and expression of P-gp via RYR/JNK/YB-1/P300 pathway, which inhibited placental and fetal development. We further demonstrated that P-gp inducer sodium ferulate could reverse the inhibitory effect of caffeine on the fetal body/placental weight. Finally, clinical specimens and other animal models of IUGR also confirmed that the JNK/YB-1 pathway is a co-regulatory mechanism of P-gp expression inhibition, among which the expression of YB-1 is the most stable. Therefore, we proposed that YB-1 could be used as the potential early warning target for the opening of the placental glucocorticoid barrier, the occurrence of IUGR, and the susceptibility of a variety of diseases. Conclusions This study, for the first time, clarified the critical role and epigenetic regulation mechanism of P-gp in mediating the opening mechanism of the placental glucocorticoid barrier, providing a novel idea for exploring the early warning, prevention, and treatment strategies of IUGR.

Glucocorticoid Receptor-Mediated Insulin-Like Growth Factor-I Transcriptional Regulation in BeWo Trophoblast Cells Before and after Syncytialisation

Dexamethasone Downregulates SLC7A5 Expression and Promotes Cell Cycle Arrest, Autophagy and Apoptosis in BeWo Cells

Impact of Axis of GHRH and GHRH Receptor on Cell Viability and Apoptosis of the Placental Choriocarcinoma Cell Line.

Dexamethasone may inhibit placental growth by blocking glucocorticoid receptors via phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin and reactive oxygen species/AMP-activated protein kinase signalling pathways in human placental JEG-3 cells

Estradiol Promotes Trophoblast Viability and Invasion by Activating SGK1

Glucocorticoid Exposure in Early Placentation Induces Preeclampsia in Rats Via Interfering Trophoblast Development.

Glucocorticoids sensitize rat placental inflammatory responses via inhibiting lipoxin A4 biosynthesis.

ABC drug transporter and nuclear receptor expression in human cytotrophoblasts: influence of spontaneous syncytialization and induction by glucocorticoids

Mechanisms for Establishment of the Placental Glucocorticoid Barrier, a Guard for Life

Prenatal Dexamethasone Exposure Exerts Sex-Specific Effect on Placental Oxygen and Nutrient Transport Ascribed to the Differential Expression of IGF2.

Regulation of Plasminogen Activator Inhibitor (PAI)-1 Expression in a Human Trophoblast Cell Line by Glucocorticoid (GC) and Transforming Growth Factor (TGF)-β

Role of Human Chorionic Gonadotropin in Maintaining 11 Beta-Hydroxysteroid Dehydrogenase Type 2 Expression in Human Placental Syncytiotrophoblasts

Intracrine Induction of 11Β-Hydroxysteroid Dehydrogenase Type 1 Expression by Glucocorticoid Potentiates Prostaglandin Production in the Human Chorionic Trophoblast1

Glucocorticoid exposure altered angiogenic factor expression via Akt/mTOR pathway in rat placenta

Integrated Transcriptome Sequencing Analysis Reveals Role of Mir-138-5p/ TBL1X in Placenta from Gestational Diabetes Mellitus

Differential Expression of Placental 11Β-Hsd2 Induced by High Maternal Glucocorticoid Exposure Mediates Sex Differences in Placental and Fetal Development.

Correction To: P-gp Expression Inhibition Mediates Placental Glucocorticoid Barrier Opening and Fetal Weight Loss.

Enhancement of glucocorticoid-induced 11beta-hydroxysteroid dehydrogenase type 1 expression by proinflammatory cytokines in cultured human amnion fibroblasts.

Decreased H3K9 Acetylation Level of LXRα Mediated Dexamethasone-Induced Placental Cholesterol Transport Dysfunction.

The Detrimental Effects of Glucocorticoids Exposure During Pregnancy on Offspring’s Cardiac Functions Mediated by Hypermethylation of Bone Morphogenetic Protein-4

The Sp1 Transcription Factor Is Crucial For The Expression Of 11 Beta-Hydroxysteroid Dehydrogenase Type 2 In Human Placental Trophoblasts